Clinical Trial Update: A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating nitric oxide reduction in patients with cardiogenic shock following a heart attack was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiogenic Shock
• Myocardial Infarction

Drugs mentioned

• Nitric Oxide Reduction

Snippet

Sponsor: Arginox Pharmaceuticals | Conditions: Shock, Cardiogenic | Phase 3 | Status: TERMINATED